Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 6Active not recruiting 6Terminated 5Recruiting 4Withdrawn 2Unknown 1

Sponsor Class

INDUSTRY 80OTHER 73NIH 4OTHER_GOV 3

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Pathologic Complete Response 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 77Biopsy 71Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 15Disulfides 15X-Rays 13Radiation 13venetoclax 12Doxorubicin 12Radiotherapy 11Gemcitabine 11durvalumab 10Prednisone 9cabozantinib 8aldesleukin 8olaparib 7decitabine and cedazuridine drug combination 7atezolizumab 7Cytarabine 7lutetium Lu 177 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × NIH × Pemetrexed × Clear all
NCT04267848 2026-05-27

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

National Cancer Institute (NCI)

Phase 3 Recruiting
1,210 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT06096844 2026-05-27

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
304 enrolled
Thoracic

Lung Neoplasms

NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡